Advertisement

Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease

  • Haruo HanyuEmail author
  • Soichiro Shimizu
  • Kentaro Hirao
  • Hidekazu Kanetaka
  • Toshihiko Iwamoto
  • Taishiro Chikamori
  • Yasuhiro Usui
  • Akira Yamashina
  • Kiyoshi Koizumi
  • Kimihiko Abe
Original Article

Abstract

Purpose

Both decreased occipital perfusion on brain single-photon emission computed tomography (SPECT) and reduction in cardiac 123I-metaiodobenzylguanidine (MIBG) uptake are characteristic features of dementia with Lewy bodies (DLB), and potentially support the clinical diagnosis of DLB. The aim of this study was to compare the diagnostic value of these two methods for differentiation of DLB from Alzheimer’s disease (AD).

Methods

The study population comprised 19 patients with probable DLB and 39 patients with probable AD who underwent both SPECT with N-isopropyl-p-[123I]iodoamphetamine and MIBG myocardial scintigraphy. Objective and quantitative measurement of perfusion in the medial occipital lobe, including the cuneus and lingual gyrus, was performed by the use of three-dimensional stereotactic surface projections.

Results

Medial occipital perfusion was significantly decreased in the DLB group compared with the AD group. The mean heart/mediastinum ratios of MIBG uptake were significantly lower in the DLB group than in the AD group. Although SPECT failed to demonstrate significant hypoperfusion in the medial occipital lobe in five patients with DLB, marked reduction of MIBG uptake was found in all patients with DLB. Receiver operating characteristic analysis revealed that MIBG myocardial scintigraphy enabled more accurate discrimination between DLB and AD than was possible with perfusion SPECT.

Conclusion

MIBG myocardial scintigraphy may improve the sensitivity in the detection of DLB. In particular, this method may provide a powerful differential diagnostic tool when it is difficult to distinguish cases of DLB from AD using brain perfusion SPECT.

Keywords

Brain SPECT Perfusion MIBG Dementia with Lewy bodies Alzheimer’s disease 

Notes

Acknowledgements

We thank J. Umeda and H. Hirose of the Department of Nuclear Medicine of Tokyo Medical University for their support and technical assistance. We are also grateful to Professor J. Patrick Barron of the International Medical Communications Center of Tokyo Medical University for his review of the manuscript.

References

  1. 1.
    McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19–28CrossRefPubMedGoogle Scholar
  2. 2.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–24PubMedGoogle Scholar
  3. 3.
    Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462–6PubMedGoogle Scholar
  4. 4.
    Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1998;51:125–30PubMedGoogle Scholar
  5. 5.
    Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247–56CrossRefPubMedGoogle Scholar
  6. 6.
    Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358–65CrossRefPubMedGoogle Scholar
  7. 7.
    Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 1999;53:413–6PubMedGoogle Scholar
  8. 8.
    Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–9PubMedGoogle Scholar
  9. 9.
    Pasquier J, Michel B, Brenot-Rossi I, Hassan-Sebbag N, Sauvan R, Gastaut JL. Value of 99mTc-ECD SPET for diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2002;29:1342–8CrossRefPubMedGoogle Scholar
  10. 10.
    Donnemiller E, Heilmann J, Wenning G, Berger W, Decristoforo C, Moncayo R, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320–5PubMedGoogle Scholar
  11. 11.
    Colloby SJ, Fenwick JD, Williams D, Paling SM, Lobotesis K, Ballard C, et al. A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging 2002;29:615–22CrossRefPubMedGoogle Scholar
  12. 12.
    Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe K. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using brain SPECT. Dement Geriatr Cogn Disord 2005;20:25–30CrossRefPubMedGoogle Scholar
  13. 13.
    Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123I-metaiodobenzyl guanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:189–94PubMedGoogle Scholar
  14. 14.
    Taki J, Nakajima K, Hwang E-H, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27:566–73CrossRefPubMedGoogle Scholar
  15. 15.
    Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999;53:1020–5PubMedGoogle Scholar
  16. 16.
    Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc J-L, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 2003;18:890–7CrossRefPubMedGoogle Scholar
  17. 17.
    Yoshita M, Taki J, Yamada M. A clinical role for [123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583–8CrossRefPubMedGoogle Scholar
  18. 18.
    Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M, et al. Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:781–3CrossRefPubMedGoogle Scholar
  19. 19.
    Oide T, Tokuda T, Momose M, Oguchi K, Nakamura A, Ohara S, et al. Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Intern Med 2003;42:686–90PubMedGoogle Scholar
  20. 20.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–44PubMedGoogle Scholar
  21. 21.
    Solanski KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513–21PubMedGoogle Scholar
  22. 22.
    Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98CrossRefPubMedGoogle Scholar
  23. 23.
    Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48PubMedGoogle Scholar
  24. 24.
    Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain. New York: Thieme; 1998Google Scholar
  25. 25.
    Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528–37PubMedGoogle Scholar
  26. 26.
    Mizumura S, Kumita S, Cho K, Ishihara M, Nakajo H, Toba M, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003;17:289–95PubMedGoogle Scholar
  27. 27.
    Kobayashi H, Momose M, Kanaya S, Kondo C, Kusakabe K, Mitsuhashi N. Scatter correction by two-window method standardizes cardiac I-123 MIBG uptake in various gamma camera systems. Ann Nucl Med 2003;17:309–13PubMedGoogle Scholar
  28. 28.
    Ballard C, Shaw F, McKeith I, Kenny RA. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology 1998;51:1760–2PubMedGoogle Scholar
  29. 29.
    Algotsson A, Viitanen M, Winblad B, Solders G. Autonomic dysfunction in Alzheimer’s disease. Acta Neurol Scand 1995;91:14–8PubMedGoogle Scholar
  30. 30.
    Wang S-J, Liao K-K, Fuh J-L, Lin K-N, Wu Z-A, Liu C-Y, et al. Cardiovascular autonomic functions in Alzheimer’s disease. Age Ageing 1994;23:400–4PubMedGoogle Scholar
  31. 31.
    Szili-Torok T, Kalman J, Paprika D, Dibo G, Rozsa Z, Rudas L. Depressed baroreflex sensitivity in patients with Alzheimer’s and Parkinson’s disease. Neurobiol Aging 2001;22:435–8CrossRefPubMedGoogle Scholar
  32. 32.
    Ishii T. Distribution of Alzheimer’s neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol 1966;6:181–7CrossRefPubMedGoogle Scholar
  33. 33.
    McDuff T, Sumi SM. Subcortical degeneration in Alzheimer’s disease. Neurology 1985;35:123–6PubMedGoogle Scholar
  34. 34.
    Yates CM, Ritchie IM, Simpson J. Noradrenalin in Alzheimer-type dementia and Down’s syndrome. Lancet 1981;ii:39–40CrossRefGoogle Scholar
  35. 35.
    Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:249–51CrossRefPubMedGoogle Scholar
  36. 36.
    Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 2004;18:453–61PubMedGoogle Scholar
  37. 37.
    Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol 2002;15:200–9PubMedGoogle Scholar
  38. 38.
    Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies. A volumetric MRI study. Neurology 1998;51:357–62PubMedGoogle Scholar
  39. 39.
    Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT. MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000;54:1304–9PubMedGoogle Scholar
  40. 40.
    Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618–30CrossRefPubMedGoogle Scholar
  41. 41.
    Hanyu H, Shimizu S, Tanaka Y, Kanetaka H, Iwamoto T, Abe K. Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimer’s disease. Neurosci Lett 2005;380:166–9CrossRefPubMedGoogle Scholar
  42. 42.
    Waker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134–40CrossRefPubMedGoogle Scholar
  43. 43.
    O’Brien JT, Colloby S, Fenwick J, Williams D, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25CrossRefPubMedGoogle Scholar
  44. 44.
    Colloby SJ, O’Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer’s disease and Parkinson’s disease. Neuroimage 2004;23:956–66CrossRefPubMedGoogle Scholar
  45. 45.
    Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practical parameter: diagnosis of dementia (an evidence-based review), report of the quality standards subcommittee of the American Academy of neurology. Neurology 2001;56:1143–53PubMedGoogle Scholar
  46. 46.
    McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Haruo Hanyu
    • 1
    Email author
  • Soichiro Shimizu
    • 1
  • Kentaro Hirao
    • 1
  • Hidekazu Kanetaka
    • 1
  • Toshihiko Iwamoto
    • 1
  • Taishiro Chikamori
    • 2
  • Yasuhiro Usui
    • 2
  • Akira Yamashina
    • 2
  • Kiyoshi Koizumi
    • 3
  • Kimihiko Abe
    • 3
  1. 1.Department of Geriatric MedicineTokyo Medical UniversityTokyoJapan
  2. 2.Second Department of Internal MedicineTokyo Medical UniversityTokyoJapan
  3. 3.Department of RadiologyTokyo Medical UniversityTokyoJapan

Personalised recommendations